- Cullinan Therapeutics (CGEM, Financial) will host an analyst and investor event on June 1, 2025, at the ASCO Annual Meeting in Chicago.
- The company will also participate in the Jefferies 2025 Global Healthcare Conference in New York from June 3-5, 2025.
- Webcasts of these events will be available on Cullinan's investor relations website.
Cullinan Therapeutics Inc. (CGEM), a biopharmaceutical firm, has announced plans to host pivotal events for investors and analysts in June 2025. The company will hold an in-person event on June 1, 2025, at 6:30 p.m. CT during the ASCO Annual Meeting in Chicago. This event will follow the presentation of the Phase 2b REZILIENT1 trial results for zipalertinib in patients with EGFR exon20 insertion NSCLC.
Furthermore, from June 3-5, 2025, Cullinan will be present at the Jefferies Global Healthcare Conference in New York. Highlights include a panel discussion on cell therapy featuring Chief Medical Officer Jeffrey Jones, M.D., M.B.A., on June 4, and a company presentation by CEO Nadim Ahmed and Jones on June 5, 2025.
Both events, showcasing Cullinan's advancements and strategic insights, will be accessible via webcast on the company’s investor relations site at Cullinan Therapeutics Events and Presentations.
